Influence of Nevirapine on HCV Viral Load

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Nevirapine-based antiretroviral therapy is associated with lower plasma HCV viral load in HIV/HCV-coinfected individuals.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Valme University Hospital
• Collaborator: Boehringer Ingelheim
• Treatments: Efavirenz; HIV Protease Inhibitors; Nevirapine; Protease Inhibitors

Criteria

Inclusion Criteria:

• HIV infection.

• Older than 18 years.

• Chronic hepatitis C.

• Undetectable HIV viral load during one year before starting study.

• To have not received HCV therapy during one year before starting study.

• To have not started efavirenz or protease inhibitors o nucleoside analogs during 6 months before starting study.

• Non contraindications for drugs included in this study.

• To change an antiretroviral regimen including efavirenz or protease inhibitors by nevirapine due to side effects, interactions or pregnancy (NVP group)

• To continue with a antiretroviral regimen including efavirenz or protease inhibitors (non-NVP group)

Both groups will be matched according to these variables:

• Liver stiffness.

• HCV genotype.

• Hospital.

• Time from starting antiretroviral therapy.

• Previous third drug (EFV or PI) to introduction of NVP.

Exclusion Criteria:

• HCV therapy during follow-up